Torcetrapib BP increase increases
Executive Summary
Preliminary results of a Phase III study of Pfizer's torcetrapib/Lipitor combination product show an average increase in systolic blood pressure of two mmHg for the HDL/LDL cholesterol combination product when compared to atorvastatin alone. "Our overall Phase III results to date...also show an average increase in systolic blood pressure of approximately one [mmHg] above the two-to-three millimeter range that was observed in Phase II studies, which we believe will not alter the favorable clinical profile of torcetrapib/atorvastatin," Pfizer Chief Medical Officer Joe Feczko says in an Oct. 31 statement. Pfizer expects to file an NDA for the compound in 2007, but has said the filing "does not anticipate a one-year approval for this compound" (1"The Pink Sheet" Oct. 23, 2006, p. 5)...
You may also be interested in...
Pfizer Torcetrapib Filing To Start ‘Dialogue,’ Not Necessarily Standard Review
Pfizer views its planned filing for its investigational HDL/LDL cholesterol combination therapy torcetrapib/Lipitor as the initiation of a dialogue between the company and FDA, not necessarily the start of a standard review
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.